Stockreport

Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy [Yahoo! Finance]

Neurogene Inc.  (NGNE) 
PDF Safety and efficacy of NGN-401 for Rett syndrome, delivered via ICV administration, to be highlighted NEW YORK, April 28, 2026 BUSINESS WIRE )--Neurogene Inc. (Nasdaq [Read more]